CIK 0001549595 · Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 270838048
- Phone
- (415) 660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +2,858 | 123,613 | ||
| 2026-04-30 | Hansen Gwenn Chief Scientific Officer | Sale | −3,214 | $16.65 | $53K | 120,399 |
| 2026-04-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −2,000 | 0 | ||
| 2026-04-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −3,750 | 15,000 | ||
| 2026-04-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −2,858 | 22,867 | ||
| 2026-04-02 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −8,148 | $15.24 | $124K | 26,453 |
| 2026-03-02 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −8,148 | $15.44 | $126K | 34,601 |
| 2026-02-10 | van Houte Hans Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +93,750 | 93,750 | ||
| 2026-02-10 | van Houte Hans Chief Financial Officer | Grant or award · Restricted Stock Units | +42,875 | 42,875 | ||
| 2026-02-10 | Ring Christine Chief Legal Officer | Grant or award · Employee Stock Option (right to buy) | +93,750 | 93,750 | ||
| 2026-02-10 | Ring Christine Chief Legal Officer | Grant or award · Restricted Stock Units | +42,875 | 42,875 | ||
| 2026-02-10 | Hansen Gwenn Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +93,750 | 93,750 | ||
| 2026-02-10 | Hansen Gwenn Chief Scientific Officer | Grant or award · Restricted Stock Units | +42,875 | 42,875 | ||
| 2026-02-10 | SANDS ARTHUR T President, CEO | Grant or award · Employee Stock Option (right to buy) | +562,500 | 562,500 | ||
| 2026-02-09 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −14,261 | $16.66 | $238K | 42,749 |
| 2026-02-03 | Hansen Gwenn Chief Scientific Officer | Option exercise | +31,333 | $0.84 | $26K | 115,005 |
| 2026-02-03 | Hansen Gwenn Chief Scientific Officer | Option exercise · Employee Stock Option (right to buy) | −31,333 | 0 | ||
| 2026-01-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,887 | 40,479 | ||
| 2026-01-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,000 | 42,479 | ||
| 2026-01-30 | van Houte Hans Chief Financial Officer | Option exercise | +3,750 | 46,229 |
Page 7 of 20 · 381 trades